Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
73°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
905.59
-36.01 (-3.82%)
Official Closing Price
Updated: 4:10 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
98
99
Next >
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
January 12, 2024
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection.
Via
Benzinga
FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts
January 11, 2024
The FDA released an update on Thursday stating that its preliminary review did not find definitive evidence that the drugs cause suicidal thoughts or actions. However, the FDA investigation will...
Via
Benzinga
Exposures
Product Safety
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.
Via
InvestorPlace
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
Eli Lilly's Options: A Look at What the Big Money is Thinking
January 10, 2024
Via
Benzinga
2 Top Healthcare Stocks to Buy Right Now
January 06, 2024
It's always a good time to invest in these excellent stocks.
Via
The Motley Fool
Pfizer’s 2024 Outlook: Is PFE Stock Poised for a Major Rebound?
January 11, 2024
Pfizer is certainly a company that will need to continue to battle headwinds moving forward, but is PFE stock worth a buy?
Via
InvestorPlace
AstraZeneca: Rebound in 2024 with double-digit earnings growth
January 11, 2024
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition
Via
MarketBeat
Exposures
COVID-19
Why Eli Lilly Stock Skyrocketed 59% in 2023
January 11, 2024
Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap.
Via
The Motley Fool
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
Via
Investor Brand Network
GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
January 10, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END
Via
FinancialNewsMedia
Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy
January 10, 2024
Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S (NYSE: NVO), shared insights during the JPMorgan Healthcare conference, highlighting Wegovy's efficacy for weight loss, indicating that patients are...
Via
Benzinga
Wall Street Doesn't Expect Eli Lilly Stock to Move Much Higher in 2024. Here's Why Analysts Could Be Wrong.
January 10, 2024
Lilly's sizzle might not fizzle in the new year.
Via
The Motley Fool
3 Simple Tricks That Every Investor Should Use (but Most Don't)
January 09, 2024
Having a few tricks up your sleeve can increase your returns over time.
Via
The Motley Fool
Where will S&P 500 go after new bullish levels?
January 09, 2024
Major indexes look resilient despite 2024's rocky start, getting support at key moving averages. Upcoming earnings could be catalysts in either direction.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles
January 09, 2024
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning
Via
Benzinga
Can Simply Good Foods ride the GLP-1 weight loss trend in 2024?
January 09, 2024
Simply Good Foods may be ready to breakout as the GLP-1 medication weight-loss trend is driving up sales for its Atkins and Quest Nutrition branded products
Via
MarketBeat
Q1’s Rising Stars: 3 Dividend Stocks with Massive Upside
January 08, 2024
Even if risk-on sentiment returns to market, there are still several catalysts nudging investors to look for dividend stocks to buy
Via
InvestorPlace
Dexcom's Recent 66% Run Continues With A Breakout On Bullish Fourth-Quarter Sales
January 08, 2024
Dexcom beat fourth-quarter sales expectations and issued stronger-than-usual annual guidance.
Via
Investor's Business Daily
Merck, the Dow's hottest stock, gets set to report Q4 financials
January 08, 2024
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery
January 08, 2024
Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google's AI R&D division DeepMind, has announced strategic part
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
January 08, 2024
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges.
Via
MarketBeat
Topics
ETFs
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis
January 07, 2024
Isomorphic Labs will get upfront cash and milestone payments.
Via
Investor's Business Daily
3 Stocks to Make You the Millionaire Next Door: 2024 Edition
January 05, 2024
Investors wanting to maximize the gains in their portfolio should take a position in one of these leading companies.
Via
InvestorPlace
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Why Is WeightWatchers (WW) Stock Down 5% Today?
January 05, 2024
Investors in Weight Watchers and WW stock are seeing more declines today, as investors price in the impact of a rival's new site.
Via
InvestorPlace
Weight-Loss Drug Boom: Philanthropy Powerhouse Emerges As Lilly Endowment Comes Closer To Gates Foundation
January 05, 2024
Weight-loss drug Mounjaro bolstered Eli Lilly's stock by almost 60% last year as stakeholder Lilly Endowment witnessed a surge in its assets.
Via
Benzinga
Stock Market Skids To Start 2024 As Tesla, Apple Stumble, Mobileye Crashes: Weekly Review
January 05, 2024
Tesla, Apple and Mobileye were key losers.
Via
Investor's Business Daily
Dry January Investing: Trading Pints For Portfolio Growth
January 05, 2024
Around 15% of Americans said they were planning to participate in Dry January — a month of abstinence from alcohol — according to a survey.
Via
Benzinga
Short Sellers' Nightmare: $195B Evaporates In 2023's Market Surge
January 05, 2024
Short sellers had a bad year, with bets on the Mag7 tech giants showing the worst losses.
Via
Benzinga
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
98
99
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.